209 related articles for article (PubMed ID: 24428908)
1. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Han K; Xu X; Chen G; Zeng Y; Zhu J; Du X; Zhang Z; Cao B; Liu Z; Mao X
J Hematol Oncol; 2014 Jan; 7():9. PubMed ID: 24428908
[TBL] [Abstract][Full Text] [Related]
2. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
3. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Mao X; Cao B; Wood TE; Hurren R; Tong J; Wang X; Wang W; Li J; Jin Y; Sun W; Spagnuolo PA; MacLean N; Moran MF; Datti A; Wrana J; Batey RA; Schimmer AD
Blood; 2011 Feb; 117(6):1986-97. PubMed ID: 21135258
[TBL] [Abstract][Full Text] [Related]
4. A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.
Tang J; Zhu J; Yu Y; Zhang Z; Chen G; Zhou X; Qiao C; Hou T; Mao X
Oncotarget; 2014 Jun; 5(11):3836-48. PubMed ID: 25003534
[TBL] [Abstract][Full Text] [Related]
5. Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.
Tian H; Zhang Y; Zhang Q; Li S; Liu Y; Han X
Biosci Trends; 2019; 13(1):40-48. PubMed ID: 30867372
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
9. Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
Chen H; Sheng H; Zhao Y; Zhu G
Med Sci Monit; 2020 Dec; 26():e928403. PubMed ID: 33382670
[TBL] [Abstract][Full Text] [Related]
10. 2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma
Zhu F; Jiang D; Zhang M; Zhao B
Pharm Biol; 2019 Dec; 57(1):641-648. PubMed ID: 31564190
[No Abstract] [Full Text] [Related]
11. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
12. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
13. A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2015 Jan; 6(1):185-95. PubMed ID: 25474140
[TBL] [Abstract][Full Text] [Related]
14. BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β-catenin/ZEB1 regulatory loop.
Zhang Q; Zhou L; Guan Y; Cheng Y; Han X
Chem Biol Interact; 2018 Oct; 294():18-27. PubMed ID: 30125547
[TBL] [Abstract][Full Text] [Related]
15. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
16. Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro.
Yin SQ; Shi M; Kong TT; Zhang CM; Han K; Cao B; Zhang Z; Du X; Tang LQ; Mao X; Liu ZP
Bioorg Med Chem Lett; 2013 Jun; 23(11):3314-9. PubMed ID: 23601711
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
18. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
19. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
[TBL] [Abstract][Full Text] [Related]
20. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
